Business Clinical trial results

Genentech's Giredestrant persevERA Study Fails

Analysis based on 10 articles · First reported Mar 09, 2026 · Last updated Mar 09, 2026

Sentiment

-10

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The market may react negatively to Roche===Genentech's announcement regarding the persevERA study, potentially causing a slight dip in Roche's stock. However, the impact is somewhat mitigated by the ongoing positive results from other Giredestrant trials and the recent FDA acceptance of a New Drug Application for Giredestrant based on evERA data.

Pharmaceuticals Biotechnology

Event Summary

Roche===Genentech, a subsidiary of Roche, announced that its Phase III persevERA Breast Cancer study, evaluating investigational Giredestrant in combination with Palbociclib for ER-positive, HER2-negative breast cancer, did not meet its primary objective of statistically significant improvement in progression-free survival. Despite this setback, a numerical improvement was observed, and the adverse events were manageable. Roche===Genentech remains confident in Giredestrant's potential, citing positive results from other trials like evERA and lidERA, and plans to submit lidERA data to the United States===Food and Drug Administration soon. The United States===Food and Drug Administration recently accepted a New Drug Application for Giredestrant based on evERA data.

Key Actions

90 Roche===Genentech announced Phase III study results

Entities Involved

subs

Roche===Genentech

Roche===Genentech announced that its Phase III persevERA Breast Cancer study for giredestrant did not meet its primary objective, which could negatively impact the company's stock and future revenue from this specific drug. However, they remain confident in giredestrant's potential in other studies.

Importance 90 Sentiment -20

stock

Roche

As the parent company of Roche===Genentech, Roche's stock may experience a slight negative impact due to the disappointing results of the persevERA study. However, the overall impact is mitigated by other ongoing giredestrant trials.

Importance 70 Sentiment -10

govactor

United States===Food and Drug Administration

The United States===Food and Drug Administration recently accepted a New Drug Application for Giredestrant based on evERA data, indicating continued regulatory progress for the drug despite the persevERA study's outcome.

Importance 30 Sentiment 0

per

Levi Garraway

Levi Garraway, as the chief medical officer of Roche===Genentech, provided a statement acknowledging the persevERA study's results while expressing continued confidence in Giredestrant's broader potential.

Importance 10 Sentiment 0

Relationships

Roche===Genentech related ↔ Roche

Levi Garraway related ↔ Roche===Genentech

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard